Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T16:11:07.078Z.
Calculation as of: 2026-10-06T16:11:07.078Z.
Quote observation: 2026-10-06T16:10:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
EARNINGS YIELD
N/A
Market Cap
$1.46B
Earnings Yield
8.04%
TTM Avg
4.29%
3Y Avg
4.28%
5Y Avg
3.97%
Market Cap
$1.44B
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.49B
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.42B
Earnings Yield
2.21%
TTM Avg
2.55%
3Y Avg
2.59%
5Y Avg
2.14%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | $1.47B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 8.04% | 4.29% | 4.28% | 3.97% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.46B | N/A | 0.64% | 0.61% | 0.61% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | 11.14% | 10.64% | 10.64% | 2.45% |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.49B | N/A | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.49B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.42B | 2.21% | 2.55% | 2.59% | 2.14% |
| Phibro Animal Health Corporation (PAHC)vs › | $1.51B | 6.57% | 5.17% | 3.51% | 4.79% |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
